iCAD granted US patent on CAD lesion metrics

NASHUA, NH, 8 March – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,660,448. This patent covers future iterations of iCAD’s SecondLook® Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions. iCAD has developed and now patented this technology, which incorporates CAD lesion metrics to provide clinicians with enhanced clinical information.

"iCAD’s R&D teams are continually striving to provide the most sophisticated image analysis solutions that incorporate feedback from our global customer base of radiology professionals," said Ken Ferry, President and CEO of iCAD. "Advancements covered by this new patent will incorporate CAD lesion metrics that can provide clinicians with insight into the system’s decision making process."

iCAD was also recently granted a U.S. patent for a Computed Tomography (CT) image analysis software development. This patent was developed to improve the way CT image analysis solutions can assess data three-dimensionally.

These patents are included among iCAD’s broad patent portfolio that is based on years of research and development on its image analysis solutions for existing and new product applications. iCAD currently has 27 granted U.S. patents and 15 U.S. patent applications pending.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer.